AI Summary
Adding daratumumab to standard treatment improves outcomes for patients with newly diagnosed multiple myeloma, with longer progression-free survival and increased likelihood of minimal residual disease.
Adding daratumumab (Darzalex) to standard treatment helped people with newly diagnosed multiple myeloma live longer without their cancer getting worse or dying. People taking daratumumab were also more likely to have no detectable signs of cancer (minimal residual disease) after treatment.